Northwest Biotherapeutics (NWBO) Change in Account Payables (2010 - 2026)

Northwest Biotherapeutics' Change in Account Payables history runs 17 years deep, the most recent figure standing at -$364000.0 for Q1 2026.

• On a quarterly basis, Change in Account Payables fell 118.02% year-over-year to -$364000.0 in Q1 2026; TTM through Mar 2026 was $3.6 million, a 4.87% decrease from a year earlier, with the FY2025 full-year figure at $5.9 million, up 554.19% from the prior year.
• Change in Account Payables eased to -$364000.0 in Q1 2026 per NWBO's latest filing, from $551000.0 in the prior quarter.
• Across five years, Change in Account Payables topped out at $2.8 million in Q2 2022 and bottomed at -$2.2 million in Q4 2023.
• The 5-year median for Change in Account Payables is $71000.0 (2022), against an average of $315411.8.
• Across the five-year window, Change in Account Payables plunged 2684.51% in 2023 and surged 715.14% in 2025, its largest moves.
• Year by year, Change in Account Payables stood at $1.2 million in 2022, then slumped by 282.31% to -$2.2 million in 2023, then jumped by 162.99% to $1.4 million in 2024, then sank by 60.89% to $551000.0 in 2025, then plunged by 166.06% to -$364000.0 in 2026.
• Per Business Quant, the three latest NWBO Change in Account Payables figures stand at -$364000.0 (Q1 2026), $551000.0 (Q4 2025), and $1.8 million (Q3 2025).